10-Q: Pacific Biosciences Reports Q1 2025 Results: Revenue Declines Amid Strategic Shift, Significant Losses Reported

Pacific Biosciences' Q1 2025 results reveal a revenue decrease and substantial operating losses as the company undergoes a strategic restructuring.

Summary

• Pacific Biosciences reported a revenue of $37.2 million for Q1 2025, a decrease from $38.8 million in the same period of 2024.
• The company experienced a gross loss of $1.4 million, compared to a gross profit of $11.3 million in Q1 2024.
• Operating loss significantly increased to $428.9 million, compared to $81.4 million in the prior year.
• Cash, cash equivalents, and investments totaled $343.1 million as of March 31, 2025, down from $389.9 million at the end of 2024.
• The company is implementing an expense reduction initiative aimed at lowering annualized run-rate operating expenses.
• A strategic shift is underway to prioritize the adoption of HiFi sequencing and cease development of the high-throughput short-read platform.
• The company recognized a $15.0 million impairment charge related to in-process research and development.
• Accelerated amortization of acquired intangible assets amounted to $359.3 million due to the change in estimated useful life of developed technology from the Omniome acquisition.
• The company amended its lease for its Menlo Park facilities, extending the term to April 30, 2034, and will pay approximately $97.7 million in base rent over the life of the amended lease.
• The company entered into a purchase agreement with CUHK to purchase the 794 patent.

Sentiment

Score: 3

Explanation: The sentiment is negative due to declining revenue, significant operating losses, and restructuring activities. While the company is taking steps to improve its financial position, the current results and near-term outlook are concerning.

Positives

• The company is actively managing its cost structure through expense reduction initiatives.
• The company is focusing on its core HiFi sequencing technology, which could lead to improved market positioning.
• The company is extending its lease for its Menlo Park facilities, securing its operational base.
• The company entered into a purchase agreement with CUHK to purchase the 794 patent.

Negatives

• Revenue decreased in Q1 2025 compared to the same period in 2024.
• The company experienced a gross loss, a significant shift from the gross profit in the prior year.
• Operating loss increased substantially due to restructuring and amortization expenses.
• Cash reserves decreased, indicating a higher cash burn rate.
• The company recognized a $15.0 million impairment charge related to in-process research and development.
• Accelerated amortization of acquired intangible assets totaled $359.3 million.

Risks

• The sales cycle for Revio instrument purchases continues to be elongated.
• Macroeconomic dynamics, including rising inflation and geopolitical tensions, could impact revenues and results of operations.
• The company may face challenges in transitioning customers to new products.
• The company's estimates could change in future periods based on events or changes in circumstances, which could result in material future impairment charges.
• The company may not have sufficient cash to make required payments under the terms of its debt or fund its long-term planned operations.
• The company may be unable to successfully develop and timely manufacture its current and future products.
• The company may be unable to consistently manufacture its instruments and consumables to the necessary specifications or in quantities necessary to meet demand at an acceptable cost or at an acceptable performance level.
• The company may be unable to convert its orders in backlog into revenue.
• The company may be unable to successfully increase sales of its current products or market and sell its future products.
• The company may be unable to compete effectively in a highly competitive industry.
• The company may be unable to secure patent or other intellectual property protection for its products and improvements to its products.
• The company may be subject to governmental regulations that may impose burdens on its operations, and the markets for its products may be narrowed.
• The company may be subject to legal proceedings with third parties who may claim that its products infringe or misappropriate their intellectual property rights.
• The company may be subject to ethical, legal, privacy, data protection and social concerns or governmental restrictions surrounding the use of genetic information.
• The price of the company's common stock has been, is, and may continue to be, highly volatile, and investors may be unable to sell their shares at or above the price they paid to acquire them.
• The company may not have the ability to raise the funds necessary to settle conversions of the Notes in cash or to repurchase the Notes upon a fundamental change, and its future debt may contain limitations on its ability to pay cash upon conversion or repurchase of the Notes.
• The Side Letter to the company's 2029 Notes imposes operating restrictions on it.
• If the Notes are converted, it may adversely affect the company's financial condition and operating results.
• Unfavorable global economic or political conditions could adversely affect the company's business, financial condition or results of operations.
• Disruption of critical information technology systems or material breaches in the security of the company's systems could harm its business, customer relations and financial condition.
• The company's use of artificial intelligence and machine learning technologies may result in reputational harm or liability.
• The company is currently subject to, and may in the future become subject to additional, U.S. federal and state laws and regulations imposing obligations on how it collects, stores and processes personal information. Its actual or perceived failure to comply with such obligations could harm its business.
• Increased scrutiny of the company's environmental, social or governance responsibilities may result in additional costs and risks, and may adversely impact its reputation, employee retention, and willingness of customers and suppliers to do business with it.

Future Outlook

The company's 2025 strategic objectives are to grow revenue and expand gross margins through enabling the full-scale release of the Vega benchtop platform, accelerating samples onto the Revio platform, investing in future product launches, and progressing its clinical strategy.

Management Comments

• The sales cycle for Revio instrument purchases continues to be elongated.
• The company believes this has been caused by, among other reasons, the uncertainty surrounding the funding for new capital equipment, in particular, uncertainty in the United States related to the National Institutes of Health (NIH) and academic funding; procurement delays; small-to-mid-size existing customers yet to increase their sample volumes to drive an upgrade to Revio; new customers, which have shown they have longer sales cycles compared to existing PacBio customers; and sample volumes materializing slower than expected for some potential Revio customers.

Industry Context

The nucleic acid sequencing industry is highly competitive, with rapid technological changes and frequent new product introductions. Pacific Biosciences faces competition from companies like Illumina, BGI Genomics, Thermo Fisher Scientific, Oxford Nanopore Technologies, and Roche.

Comparison to Industry Standards

• It is difficult to compare Pacific Biosciences' results directly to industry standards without detailed competitor data.
• Illumina, as the market leader, typically sets the benchmark for revenue and gross margins in the sequencing industry.
• Thermo Fisher Scientific, with its diverse portfolio, provides a broader comparison point for revenue growth and profitability.
• Oxford Nanopore Technologies, a key competitor in long-read sequencing, offers an alternative technology with different strengths and weaknesses.
• Bionano Genomics, focusing on optical genome mapping, targets a different segment of the market but competes for research funding.
• Roche, with its history in sequencing, is developing potentially competing sequencing products.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in ongoing patent infringement litigation with Personal Genomics of Taiwan, Inc. (PGI) in the U.S. District Court for the Northern District of California.
• The company is involved in ongoing patent infringement litigation with Take2 Technologies, Ltd. and the Chinese University of Hong Kong (CUHK) in the U.S. District Court for the Northern District of California.
• On March 7, 2025, the company entered into a purchase agreement with CUHK to purchase the 794 patent, which is related to the Take2 litigation.
• PGI filed a complaint in the Wuhan Intermediate Peoples Court in China alleging infringement of one or more claims of China patent No. CN101743321B (the CN321 Patent), which is related to the 441 Patent. On November 23, 2020 we filed an Invalidation Petition at the China National Intellectual Property Administration (CNIPA) demonstrating the invalidity of the claims in the CN321 Patent on grounds of insufficient disclosure, and the lack of support, essential technical features, clarity, novelty, and inventiveness. A hearing in the invalidation proceeding at the CNIPA was held on April 29, 2021. On September 2, 2021, the CNIPA issued its decision on the Invalidation Petition and determined that all claims (1-61) of the CN321 patent were invalid. On December 1, 2021, PGI filed an appeal with the Beijing IP Court, contesting the CNIPA decision. We filed a petition with the Wuhan Intermediate Peoples court requesting dismissal of the infringement action based on the CNIPA invalidation decision, and PGI filed a petition to withdraw its complaint. The Wuhan Intermediate Peoples court granted PGIs petition and dismissed the infringement action in May 2022.

Stakeholder Impact

• Shareholders: Dilution may occur from potential equity issuances; stock price may be volatile.
• Employees: Workforce reductions and restructuring may impact morale and job security.
• Customers: Focus on HiFi sequencing may lead to improved products, but transition may cause disruption.
• Suppliers: Potential changes in supply chain due to tariffs and trade restrictions.
• Creditors: Ability to repay debt may be affected by financial performance.

Next Steps

• Enable the full-scale release of the Vega benchtop platform.
• Accelerate samples onto the Revio platform via SPRQ chemistry and application kits.
• Invest in future product launches to diversify offerings.
• Progress the clinical strategy to improve outcomes and create durability.

Key Dates

Keywords

HiFi sequencing, Revio, Vega, Financial results, Restructuring, Impairment, Pacific Biosciences, Genomics, Sequencing, Revenue